Neoplasms – Page 6

GE HealthCare and UCSF Launch ‘Care Innovation Hub’ to Revolutionize Medical Imaging for Cancer and Neurodegenerative Diseases

7 months ago talkbio0Tagged Automated (qualifier value), brain health, ELAVL2 gene, GE HealthCare, innovation, Magnetic Resonance Imaging, Medical Imaging, Neoplasms, Neurodegenerative Disorders, Precision - temporal, radiopharmaceutical therapies, UCSF

GE HealthCare, UCSF, Care Innovation Hub, medical imaging, cancer, neurodegenerative diseases, precision oncology, brain health, automated imaging techniques, MRI, radiopharmaceutical therapies.

Numab Therapeutics Secures Additional $55 Million in Series C Funding to Advance Multi-Specific Antibody Therapies

8 months ago talkbio0Tagged Biotechnology, Immunotherapy, Inflammation, multi-specific antibodies, Neoplasms, Numab, Series C

Numab Therapeutics, Series C Funding, Multi-Specific Antibodies, Immunotherapy, Oncology, Inflammation, Biotechnology

Synaffix Expands ADC Licensing Partnerships with Boehringer Ingelheim and Mitsubishi Tanabe

8 months ago talkbio0Tagged Boehringer, Cancer Therapeutic Procedure, Ingelheim, licensing agreement, Mitsubishi Tanabe, Neoplasms, Synaffix, Technology, therapeutic autologous dendritic cells

Synaffix, Boehringer Ingelheim, Mitsubishi Tanabe, ADC technology, oncology, cancer treatment, licensing agreement

Novo Nordisk and Lilly Lead Clarivate’s 2025 ‘Drugs to Watch’ List with Breakthrough Therapies

8 months ago talkbio0Tagged blockbuster drugs, Clarivate, Drug Industry, Eli, Eli Lilly, gene therapy, Neoplasms, Nordisk, Obesity

Clarivate, Drugs to Watch 2025, Novo Nordisk, Eli Lilly, Obesity treatments, Gene therapy, Oncology, Blockbuster drugs, Pharmaceutical industry

Gilead CEO Daniel O’Day Welcomes Former Colleague Dietmar Berger as New Chief Medical Officer

8 months ago talkbio0Tagged Chief Medical Officer, Daniel, Dietmar Berger, Gilead Sciences, Neoplasms, O'Day, sanofi

Daniel O’Day, Gilead Sciences, Dietmar Berger, Sanofi, Chief Medical Officer, Oncology

Breakthroughs in Bladder Cancer Treatment: Protara and CG Oncology Report Encouraging Outcomes

9 months ago talkbio0Tagged Carcinoma of urinary bladder, invasive, Cell Therapy, centigram, Cretostimogene Grenadenorepvec, Lyophilized Inactivated Group A Streptococcus TARA-002, Malignant Neoplasms, Neoplasms, Non-Muscle, Non-Muscle Invasive Bladder Neoplasms, Oncolytic Immunotherapy, Protara Therapeutics, Urinary Bladder

Bladder Cancer Treatment, Protara Therapeutics, CG Oncology, TARA-002, Cretostimogene Grenadenorepvec, Non-Muscle Invasive Bladder Cancer (NMIBC), Oncolytic Immunotherapy, Cell Therapy